Interpace Biosciences, Inc.
IDXG
Interpace Biosciences, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $38.7 million, down 17.5% from fiscal 2024. In the quarter to June 2026, revenue fell 1.09%, EPS grew 104.1% and free cash flow fell 92.1%, each against the same quarter a year earlier. Operating cash flow growth for five consecutive years.
Follow IDXG
A Balance Sheet is a financial statement that provides a snapshot of a company's assets, liabilities, and shareholders' equity at a specific point in time. It follows the formula: Assets = Liabilities + Shareholders' Equity. Key components include current and non-current assets, current and long-term liabilities, and equity. The Balance Sheet helps businesses and investors evaluate financial stability, liquidity, and capital structure. It's essential for assessing the company's ability to meet its obligations and fund future operations.
| Dec '16 | Dec '17 | Dec '18 | Dec '19 | Dec '20 | Dec '21 | Dec '22 | Dec '23 | Dec '24 | Dec '25 | |
|---|---|---|---|---|---|---|---|---|---|---|
Cash and Short Term Investments |
0.60 | 15.20 | 6.07 | 2.32 | 3.37 | 2.92 | 4.83 | 3.50 | 1.46 | 2.51 |
Receivables |
2.21 | 3.44 | 9.48 | 10.34 | 8.03 | 4.67 | 5.03 | 5.08 | 8.54 | 5.65 |
Other current assets |
1.42 | 1.17 | 2.17 | 3.85 | 2.72 | 1.48 | 2.29 | 1.84 | 1.77 | 1.75 |
Total current assets |
4.24 | 19.81 | 17.72 | 16.51 | 14.12 | 12.17 | 12.15 | 10.42 | 11.77 | 9.90 |
Property, Plant, Equpment (Net) |
0.93 | 0.65 | 0.84 | 6.81 | 7.35 | 0.32 | 0.48 | 0.79 | 1.36 | 1.42 |
Goodwill and Intangible Assets (Total) |
36.36 | 33.11 | 12.54 | 24.28 | 19.78 | 2.13 | 0.86 | — | — | — |
Long Term Assets (Tax, Deferred) |
— | — | — | — | — | — | — | — | — | 21.25 |
Long-term assets (Other) |
0.25 | 0.03 | 0.03 | 0.04 | 0.04 | 0.14 | 0.05 | 0.05 | 0.05 | 0.04 |
Total non-current assets |
37.54 | 33.79 | 13.41 | 35.03 | 31.56 | 26.26 | 3.83 | 2.70 | 3.02 | 23.94 |
Total Assets |
41.78 | 53.60 | 31.13 | 51.54 | 45.68 | 38.43 | 15.98 | 13.12 | 14.79 | 33.84 |
Notes Payable |
— | — | — | — | — | — | — | 5.10 | 4.29 | — |
Accounts Payable |
2.33 | 0.39 | 1.06 | 4.71 | 4.51 | 1.37 | 1.05 | 1.54 | 1.66 | 0.98 |
Accrued Expenses |
3.55 | 1.39 | 1.54 | 2.34 | 3.16 | 2.69 | 1.46 | 1.97 | 2.21 | 1.89 |
Current Part of Debt |
— | — | — | — | — | — | 2.50 | — | — | — |
Total current liabilities |
16.24 | 8.09 | 8.67 | 17.29 | 18.23 | 15.68 | 14.28 | 11.44 | 10.62 | 5.10 |
Long Term Debt (Total) |
7.91 | — | — | 3.00 | — | 9.44 | 11.17 | 4.24 | — | — |
Liabilities (Preferred Stock) |
— | — | — | 26.17 | 46.54 | 46.54 | 46.54 | 46.54 | — | — |
Non-current Liabilities (Other) |
11.10 | 5.64 | 7.01 | 6.96 | 6.46 | 5.96 | 5.22 | 4.97 | 5.21 | 5.62 |
Total non-current liabilities |
19.01 | 5.64 | 7.01 | 38.73 | 56.53 | 65.16 | 64.77 | 57.22 | 6.39 | 6.37 |
Total liabilities |
35.25 | 13.73 | 15.68 | 56.02 | 74.76 | 80.85 | 79.05 | 68.66 | 17.01 | 11.48 |
Additional Paid In Capital |
127.74 | 173.06 | 175.82 | 182.51 | 184.40 | 186.11 | 187.52 | 188.15 | 234.81 | 234.83 |
Common Stock (Net) |
0.02 | 0.28 | 0.29 | 0.39 | 0.40 | 0.40 | 0.41 | 0.41 | 0.41 | 0.41 |
Retained Earnings |
(119.58) | (131.80) | (158.98) | (185.66) | (212.12) | (227.06) | (249.02) | (242.08) | (235.38) | (210.80) |
Treasury Stock |
1.64 | 1.67 | 1.68 | 1.72 | 1.77 | 1.87 | 1.98 | 2.01 | 2.05 | 2.07 |
Common Equity (Total) |
6.53 | 39.87 | 15.45 | (4.48) | (29.08) | (42.42) | (63.07) | (55.54) | (2.22) | 22.36 |
Shareholders Equity (Total) |
6.53 | 39.87 | 15.45 | (4.48) | (29.08) | (42.42) | (63.07) | (55.54) | (2.22) | 22.36 |
Shareholders Equity and Liabilities (Total) |
41.78 | 53.60 | 31.13 | 51.54 | 45.68 | 38.43 | 15.98 | 13.12 | 14.79 | 33.84 |
Shares (Common) |
0.04 | 0.56 | 0.57 | 0.78 | 0.81 | 0.84 | 0.86 | 0.87 | 0.88 | 0.89 |
Shareholders Equity (Tangible) |
(29.83) | 6.76 | 2.91 | (28.76) | (48.87) | (44.55) | (63.93) | (55.54) | (2.22) | 22.36 |
Net Debt |
7.31 | (15.20) | (6.07) | 0.68 | (3.37) | 6.52 | 8.84 | 0.75 | (1.46) | (2.50) |
Total Debt |
7.91 | — | — | 3.00 | — | 9.44 | 13.67 | 4.24 | — | — |